Radiogenomics: Using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy

Sarah L. Kerns, Harry Ostrer, Barry S. Rosenstein

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Normal-tissue adverse effects following radiotherapy are common and signifi - cantly affect quality of life. These effects cannot be accounted for by dosimetric, treatment, or demographic factors alone, and evidence suggests that common genetic variants are associated with radiotherapy adverse effects. The field of radiogenomics has evolved to identify such genetic risk factors. Radiogenomics has two goals: (i) to develop an assay to predict which patients with cancer are most likely to develop radiation injuries resulting from radiotherapy, and (ii) to obtain information about the molecular pathways responsible for radiation-induced normal-tissue toxicities. This review summarizes the history of the field and current research.

Original languageEnglish (US)
Pages (from-to)155-165
Number of pages11
JournalCancer Discovery
Volume4
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Radiotherapy
Neoplasms
Radiation Injuries
History
Quality of Life
Demography
Radiation
Research
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Radiogenomics : Using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy. / Kerns, Sarah L.; Ostrer, Harry; Rosenstein, Barry S.

In: Cancer Discovery, Vol. 4, No. 2, 2014, p. 155-165.

Research output: Contribution to journalArticle

@article{bf34714e93f445e8987a438fb877afdf,
title = "Radiogenomics: Using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy",
abstract = "Normal-tissue adverse effects following radiotherapy are common and signifi - cantly affect quality of life. These effects cannot be accounted for by dosimetric, treatment, or demographic factors alone, and evidence suggests that common genetic variants are associated with radiotherapy adverse effects. The field of radiogenomics has evolved to identify such genetic risk factors. Radiogenomics has two goals: (i) to develop an assay to predict which patients with cancer are most likely to develop radiation injuries resulting from radiotherapy, and (ii) to obtain information about the molecular pathways responsible for radiation-induced normal-tissue toxicities. This review summarizes the history of the field and current research.",
author = "Kerns, {Sarah L.} and Harry Ostrer and Rosenstein, {Barry S.}",
year = "2014",
doi = "10.1158/2159-8290.CD-13-0197",
language = "English (US)",
volume = "4",
pages = "155--165",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Radiogenomics

T2 - Using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy

AU - Kerns, Sarah L.

AU - Ostrer, Harry

AU - Rosenstein, Barry S.

PY - 2014

Y1 - 2014

N2 - Normal-tissue adverse effects following radiotherapy are common and signifi - cantly affect quality of life. These effects cannot be accounted for by dosimetric, treatment, or demographic factors alone, and evidence suggests that common genetic variants are associated with radiotherapy adverse effects. The field of radiogenomics has evolved to identify such genetic risk factors. Radiogenomics has two goals: (i) to develop an assay to predict which patients with cancer are most likely to develop radiation injuries resulting from radiotherapy, and (ii) to obtain information about the molecular pathways responsible for radiation-induced normal-tissue toxicities. This review summarizes the history of the field and current research.

AB - Normal-tissue adverse effects following radiotherapy are common and signifi - cantly affect quality of life. These effects cannot be accounted for by dosimetric, treatment, or demographic factors alone, and evidence suggests that common genetic variants are associated with radiotherapy adverse effects. The field of radiogenomics has evolved to identify such genetic risk factors. Radiogenomics has two goals: (i) to develop an assay to predict which patients with cancer are most likely to develop radiation injuries resulting from radiotherapy, and (ii) to obtain information about the molecular pathways responsible for radiation-induced normal-tissue toxicities. This review summarizes the history of the field and current research.

UR - http://www.scopus.com/inward/record.url?scp=84893439855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893439855&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-13-0197

DO - 10.1158/2159-8290.CD-13-0197

M3 - Article

C2 - 24441285

AN - SCOPUS:84893439855

VL - 4

SP - 155

EP - 165

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 2

ER -